We are contrasting Array BioPharma Inc. (NASDAQ:ARRY) and Arcturus Therapeutics Ltd. (NASDAQ:ARCT) on their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Array BioPharma Inc.	180.09M	28.61	111.47M	-0.53	0.00
Arcturus Therapeutics Ltd.	15.75M	5.34	21.79M	-4.19	0.00

In table 1 we can see Array BioPharma Inc. and Arcturus Therapeutics Ltd.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 represents Array BioPharma Inc. (NASDAQ:ARRY) and Arcturus Therapeutics Ltd. (NASDAQ:ARCT)’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Array BioPharma Inc.	-61.90%	-45.1%	-22.4%
Arcturus Therapeutics Ltd.	-138.35%	0%	0%

Risk & Volatility

A beta of 1.49 shows that Array BioPharma Inc. is 49.00% more volatile than Standard and Poor’s 500. Competitively, Arcturus Therapeutics Ltd.’s beta is 2.09 which is 109.00% more volatile than Standard and Poor’s 500.

Liquidity

6.3 and 6.3 are the respective Current Ratio and a Quick Ratio of Array BioPharma Inc. Its rival Arcturus Therapeutics Ltd.’s Current and Quick Ratios are 2.5 and 2.5 respectively. Array BioPharma Inc. has a better chance of clearing its pay short and long-term debts than Arcturus Therapeutics Ltd.

Analyst Ratings

Array BioPharma Inc. and Arcturus Therapeutics Ltd. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Array BioPharma Inc.	0	1	4	2.80
Arcturus Therapeutics Ltd.	0	0	1	3.00

The average price target of Array BioPharma Inc. is $25.5, with potential upside of 8.01%. Competitively Arcturus Therapeutics Ltd. has a consensus price target of $15, with potential upside of 91.82%. The information presented earlier suggests that Arcturus Therapeutics Ltd. looks more robust than Array BioPharma Inc. as far as analyst opinion.

Insider and Institutional Ownership

Array BioPharma Inc. and Arcturus Therapeutics Ltd. has shares owned by institutional investors as follows: 0% and 14.6%. Insiders owned 0.4% of Array BioPharma Inc. shares. Comparatively, insiders own roughly 23.9% of Arcturus Therapeutics Ltd.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Array BioPharma Inc.	0.72%	26.73%	45.15%	53.84%	33.98%	66.04%
Arcturus Therapeutics Ltd.	3.88%	1.8%	-16.69%	-36.69%	-7.96%	12.36%

For the past year Array BioPharma Inc. was more bullish than Arcturus Therapeutics Ltd.

Summary

Array BioPharma Inc. beats Arcturus Therapeutics Ltd. on 7 of the 12 factors.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Arcturus Therapeutics Ltd. operates as an RNA medicines company. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries. Its proprietary UNA technology is used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. The company develops novel RNA therapeutics through its partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., and Cystic Fibrosis Foundation Therapeutics Inc. Arcturus Therapeutics Ltd. has a strategic collaboration with CureVac AG to jointly discover, develop, and commercialize novel messenger RNA therapeutics. The company was founded in 2013 and is headquartered in San Diego, California.